Durvalumab and Tremelimumab in Resectable HCC

NCT05440864 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

28

Enrollment

OTHER

Sponsor class

Conditions

Hepatocellular Carcinoma

Interventions

DRUG: Tremelimumab

Sponsor

University Health Network, Toronto

Collaborators

[object Object]
[object Object]